SCHEMBL3424112

SCHEMBL3424112

Cc1cc(OCCCC2CCN(C(=O)OC(C)(C)C)CC2)ccc1C=O

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 15/20 0.62
CHEK2 O96017 1/20 0.49
FAAH O00519 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575856 0.85 GPR119 (0.64) GPR119FAAH
SCHEMBL1296310 0.84 GPR119 (0.63) GPR119CHEK2FAAH
SCHEMBL1575966 0.84 GPR119 (0.80) GPR119
SCHEMBL30984093 0.83 GPR4 (0.51) GPR119
SCHEMBL1295322 0.83 GPR119 (0.61) GPR119CHEK2
SCHEMBL31575002 0.82 GPR119 (0.65) GPR119FAAH
SCHEMBL1575797 0.82 GPR119 (0.63) GPR119FAAH
SCHEMBL1295724 0.82 GPR119 (0.62) GPR119FAAH
SCHEMBL3342813 0.82 GPR119 (0.55) GPR119CHEK2
SCHEMBL8696526 0.81 GPR119 (0.58) GPR119FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723527-B2 Benzoimidazole compounds JANSSEN PHARMACEUTICA NV (BE) 2010-05-25 US disclosed
US-7723526-B2 Benzoimidazole compounds JANSSEN PHARMACEUTICA NV (BE) 2010-05-25 US disclosed
US-7723359-B2 Benzoimidazole compounds JANSSEN PHARMACEUTICA NV (BE) 2010-05-25 US disclosed
US-7705149-B2 Benzoimidazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2010-04-27 US disclosed
US-7705143-B2 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-[1,4]diazepan-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions JANSSEN PHARMACEUTICA N.V. (BG) 2010-04-27 US disclosed
US-7662966-B2 For example, 5-tert-Butyl-2-{2-[4-(1-methyl-piperidin-4-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-16 US disclosed
US-20090281307-A1 Benzoimidazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-12 US disclosed
US-20090275748-A1 Benzoimidazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-05 US disclosed
US-20090270611-A1 Benzoimidazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-29 US disclosed
US-20090270366-A1 Benzoimidazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-29 US disclosed
US-20090270613-A1 Benzoimidazole compounds EDWARDS JAMES P 2009-10-29 US disclosed
US-20090264647-A1 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-22 US disclosed
US-20090264646-A1 Benzoimidazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-22 US disclosed
US-20090264645-A1 Benzoimidazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-22 US disclosed
US-20090247508-A1 Benzoimidazole Compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-01 US disclosed
EP-1673348-B1 BENZOIMIDAZOLE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2009-04-01 EP disclosed
US-7432378-B2 Benzoimidazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2008-10-07 US disclosed
EP-1673348-A2 BENZOIMIDAZOLE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-28 EP disclosed
WO-2005044807-A2 BENZOIMIDAZOLE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2005-05-19 WO disclosed
US-20050070550-A1 Benzoimidazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270613-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885
US-20090264646-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885
US-20050070550-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885
US-20090270366-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885
US-20090270611-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885
US-20090275748-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885
US-20090264647-A1 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation HRH4, HRH3, BRD4 GPR119 499/4885CHEK2 3691/4885FAAH 1333/4885
US-20090247508-A1 Benzoimidazole Compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885
US-20090264645-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885
US-20090281307-A1 Benzoimidazole compounds HRH4, HRH3, BRD4 GPR119 309/4885CHEK2 2908/4885FAAH 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.